Isoindolines, method of use, and pharmaceutical compositions
US6316471A · kind A · utility
159Cited by
27References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2000 |
| Grant date | Nov 13, 2001 |
| Priority date | — |
| Expiry date | Oct 17, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.